环丝氨酸治疗结核病的临床用药指南

目前,结核病疫情仍然较为严重。环丝氨酸作为治疗耐药结核病的核心药品,缺乏具体的相关规范性指导意见。中国防痨协会临床试验专业分会、《中国防痨杂志》编辑委员会组织专家通过深入研究与讨论,制定了《环丝氨酸治疗结核病的临床用药指南》(简称“《指南》”)。本《指南》介绍了环丝氨酸的分子结构和作用机制、药效学与药代动力学、药物相互作用、耐药机制、有效性和安全性、特殊人群应用、适应证和禁忌证、剂量用法、不良反应监测与处理、临床应用注意事项等内容,以期指导医护人员规范、合理地使用环丝氨酸。

Guideline for clinical application of cycloserine in the treatment of tuberculosis

Recently, the tuberculosis epidemic is serious. Cycloserine, as the core drug in the treatment of drug-resistant tuberculosis, lacks the relevant guidance. The Clinical Trial Branch of the Chinese Antituberculosis Association and the Editorial Board of the Chinese Journal of Antituberculosis organized relevant experts to discuss deeply and to develop this guideline. This guideline introduces the molecular structure and mechanism of action, pharmacodynamics, pharmacokinetics, drug interaction, drug resistance mechanism, efficacy and safety, usage of special population, indications and contraindications, dosage and usage, drug adverse effect and clinical attentions, so as to help medical staff to standardize and reasonably use cycloserine.